Pasar al contenido principal

NUEVOS CANDIDATOS ANTIVIRALES FRENTE A LA RIBONUCLEASA H DEL VIH Y ESTRUCTURAS ANALOGAS DE OTROS VIRUS E INGENIERIA DE RETROTRANSCRIPTASAS

PID2022-136725OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges

  • Du, Shaoqing
  • Hu, Xueping
  • Menéndez-Arias, Luis
  • Zhan, Peng
  • Liu, Xinyong
Viral infections have a major impact in human health. Ongoing viral transmission and escalating selective pressure have the potential to favor the emergence of vaccine- and antiviral drug-resistant viruses. Target-based approaches for the design of antiviral drugs can play a pivotal role in combating drug-resistant challenges. Drug design computational tools facilitate the discovery of novel drugs. This review provides a comprehensive overview of current drug design strategies employed in the field of antiviral drug resistance, illustrated through the description of a series of successful applications. These strategies include technologies that enhance compound-target affinity while minimizing interactions with mutated binding pockets. Furthermore, emerging approaches such as virtual screening, targeted protein/RNA degradation, and resistance analysis during drug design have been harnessed to curtail the emergence of drug resistance. Additionally, host targeting antiviral drugs offer a promising avenue for circumventing viral mutation. The widespread adoption of these refined drug design strategies will effectively address the prevailing challenge posed by antiviral drug resistance., We gratefully acknowledge financial support from the National Natural Science Foundation of China (Nos. 22208191, 22273049), the Development Plan for Youth Innovation Team of Shandong Province (2023KJ011), the Program of Young Scholars Future Program of Shandong University, Major Basic Research Project of Shandong Provincial Natural Science Foundation (ZR2021ZD17), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31), Foreign Cultural and Educational Experts Project (GXL20200015001), Guangdong Basic and Applied Basic Research Foundation (2021A1515110740), Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China (Grant No. 2023YFC2606500). This work was supported in part by the Ministry of Science, Innovation and Universities of Spain through grant PID2022-136725OB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. An institutional grant of the Fundación Ramón Areces (Madrid, Spain) to the CBMSO is also acknowledged. The CBMSO has been certified since 2023 as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. L. M.-A. is member of the Global Virus Network.